GlassScriptPhysician profile
Maxim Shulimovich
NPI 1326297318
$2,427.89
in general payments reported to CMS, 2019-2025
35 companies · $55.27 in 2025
The $55.27 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $326 · 2021: $327 · 2022: $177 · 2023: $151 · 2024: $52.50 · 2025: $55.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176 · Education: $83.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.65 |
| Education | $83.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $317.15 | 2019-2020 | |
| Exelixis INC. | $177.15 | 2019-2023 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $162.47 | 2019 | |
| Genzyme Corporation | $147.51 | 2019-2023 | |
| Genentech USA, INC. | $139.13 | 2019-2020 | |
| Pfizer INC. | $136.12 | 2019-2025 | |
| Kite Pharma, INC. | $135.91 | 2020-2022 | |
| Dova Pharmaceuticals | $125.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $83.51 | 2019-2020 | |
| Gilead Sciences, INC. | $79.84 | 2019-2021 | |
| Janssen Biotech, INC. | $69.18 | 2021 | |
| Abbvie INC. | $65.83 | 2019-2020 | |
| Tesaro, INC. | $64.29 | 2019 | |
| Incyte Corporation | $64.15 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $60.43 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $53.53 | 2019 | |
| Eisai INC. | $52.50 | 2024 | |
| Seagen INC. | $46.95 | 2021-2022 | |
| Amgen INC. | $45.50 | 2020 | |
| Sobi, INC | $32.28 | 2023 | |
| Celgene Corporation | $26.35 | 2019 | |
| Azurity Pharmaceuticals, INC. | $24.62 | 2025 | Danziten |
| Immunomedics, INC. | $24.48 | 2020 | |
| Epizyme, INC. | $23.57 | 2020 | |
| Shield Therapeutics INC | $22.73 | 2023 | Accrufer |
| Ipsen Biopharmaceuticals, INC | $20.61 | 2019 | |
| Dendreon Pharmaceuticals LLC | $20.44 | 2022 | |
| Kyowa Kirin, INC. | $19.90 | 2019 | |
| Global Blood Therapeutics, INC. | $19.30 | 2021 | |
| Rigel Pharmaceuticals, INC. | $18.39 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.45 | 2020 | |
| Heron Therapeutics, INC. | $13.37 | 2022 | |
| Myriad Genetic Laboratories, INC. | $12.39 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxim Shulimovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.